547 results on '"Chon, Chae Yoon"'
Search Results
2. CCR Translation for This Article from Number of Target Lesions for EASL and Modified RECIST to Predict Survivals in Hepatocellular Carcinoma Treated with Chemoembolization
3. Supplementary Table 1 from Number of Target Lesions for EASL and Modified RECIST to Predict Survivals in Hepatocellular Carcinoma Treated with Chemoembolization
4. Supplementary Figure 2 from Number of Target Lesions for EASL and Modified RECIST to Predict Survivals in Hepatocellular Carcinoma Treated with Chemoembolization
5. Supplementary Table 3 from Number of Target Lesions for EASL and Modified RECIST to Predict Survivals in Hepatocellular Carcinoma Treated with Chemoembolization
6. Supplementary Figure 1 from Number of Target Lesions for EASL and Modified RECIST to Predict Survivals in Hepatocellular Carcinoma Treated with Chemoembolization
7. Supplementary Figure Legend from Number of Target Lesions for EASL and Modified RECIST to Predict Survivals in Hepatocellular Carcinoma Treated with Chemoembolization
8. Noninvasive Prediction of Erosive Esophagitis Using a Controlled Attenuation Parameter (CAP)-Based Risk Estimation Model
9. The Efficacy of the Ultrasonographic Screening Test for Early Detection of Hepatocellular Carcinoma and Risk Factors of HCC in Korea
10. Prognostic value of the 7th edition of the AJCC staging system as a clinical staging system in patients with hepatocellular carcinoma
11. Gastroduodenal Complications After Concurrent Chemoradiation Therapy in Patients With Hepatocellular Carcinoma: Endoscopic Findings and Risk Factors
12. Can preoperative diffusion-weighted MRI predict postoperative hepatic insufficiency after curative resection of HBV-related hepatocellular carcinoma? A pilot study
13. Maintaining remission in lamivudine-resistant patients with a virological response to adefovir add-on lamivudine after stopping lamivudine therapy
14. Early Predictor of Mortality due to Irreversible Posthepatectomy Liver Failure in Patients with Hepatocellular Carcinoma
15. Combination treatment of localized concurrent chemoradiation therapy and transarterial chemoembolization in locally advanced hepatocellular carcinoma with intrahepatic metastasis
16. Prediction of Recurrence after Curative Resection of Hepatocellular Carcinoma using Liver Stiffness Measurement (FibroScan®)
17. Liver Stiffness Measurement Using Acoustic Radiation Force Impulse (ARFI) Elastography and Effect of Necroinflammation
18. Clevudine-induced viral response, associated with continued reduction of HBsAg titer, was durable after the withdrawal of therapy
19. Non-invasive assessment of changes in liver fibrosis via liver stiffness measurement in patients with chronic hepatitis B: impact of antiviral treatment on fibrosis regression
20. External Validation of P2/MS and Comparison with Other Simple Non-invasive Indices for Predicting Liver Fibrosis in HBV-Infected Patients
21. Usefulness of FibroScan for Detection of Early Compensated Liver Cirrhosis in Chronic Hepatitis B
22. Clinical usefulness of double biomarkers AFP and PIVKA-II for subdividing prognostic groups in locally advanced hepatocellular carcinoma
23. Controlled attenuation parameter (CAP) for detection of hepatic steatosis in patients with chronic liver diseases: a prospective study of a native Korean population
24. Prediction of postoperative hepatic insufficiency by liver stiffness measurement (FibroScan®) before curative resection of hepatocellular carcinoma: a pilot study
25. Hepatocellular carcinoma presenting with bone metastasis: clinical characteristics and prognostic factors
26. What is the role of diagnostic laparoscopy in a gastroenterology unit?
27. Normal enhanced liver fibrosis (ELF) values in apparently healthy subjects undergoing a health check-up and in living liver donors in South Korea
28. Combined measurement of preoperative α-fetoprotein and des-γ-carboxy prothrombin predicts recurrence after curative resection in patients with hepatitis-B-related hepatocellular carcinoma
29. Hepatic stellate cells primed with cytokines upregulate inflammation in response to peptidoglycan or lipoteichoic acid
30. Comparison of treatment efficacy between sorafenib monotherapy and sorafenib-based combination therapy in advanced hepatocellular carcinoma: 613
31. Liver stiffness values using transient elastography can predict the development of liver-related events during 2-year entecavir treatment in patients with chronic hepatitis B: 490
32. Maintenance of remission among lamivudine-resistant patients with complete virological response to adefovir add-on lamivudine after stopping lamivudine therapy: Interim analysis at 72 weeks: 439
33. The Fate of Chronic Hepatitis B in the Era of Antiviral Therapy: 352
34. Antiviral efficacy of lamivudine versus entecavir in patients with hepatitis B virus-related advanced hepatocellular carcinoma
35. Lamivudine plus adefovir vs. entecavir in HBeAg-positive hepatitis B with sequential treatment failure of lamivudine and adefovir
36. Predictive value of HBsAg quantification for determining the clinical course of genotype C HBeAg-negative carriers
37. “Normal” liver stiffness values differ between men and women: A prospective study for healthy living liver and kidney donors in a native Korean population
38. Early on-treatment predictions of clinical outcomes using alpha-fetoprotein and des-gamma-carboxy prothrombin responses in patients with advanced hepatocellular carcinoma
39. Normal liver elasticity values using acoustic radiation force impulse imaging: A prospective study in healthy living liver and kidney donors
40. Transitional features of histologic type of non-alcoholic fatty liver disease in Korean young men
41. Clinical features and prognosis of hepatocellular carcinoma with respect to pre-S deletion and basal core promoter mutations of hepatitis B virus Genotype C2
42. Treatment of recurrent hepatocellular carcinoma after liver transplantation
43. Oltipraz therapy in patients with liver fibrosis or cirrhosis: a randomized, double-blind, placebo-controlled phase II trial
44. Quantitative hepatitis B surface antigen and hepatitis B e antigen titers in prediction of treatment response to entecavir
45. Risk Assessment of Hepatitis B Virus–Related Hepatocellular Carcinoma Development Using Liver Stiffness Measurement (FibroScan)σ
46. Efficacy of adefovir add-on lamivudine rescue therapy compared with switching to entecavir monotherapy in patients with lamivudine-resistant chronic hepatitis B*,†
47. A novel liver stiffness measurement-based prediction model for cirrhosis in hepatitis B patients
48. Prospective validation of P2/MS noninvasive index using complete blood counts for detecting oesophageal varices in B-viral cirrhosis
49. Validation of FIB-4 and comparison with other simple noninvasive indices for predicting liver fibrosis and cirrhosis in hepatitis B virus-infected patients
50. What are ‘true normal’ liver stiffness values using FibroScan®?: a prospective study in healthy living liver and kidney donors in South Korea
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.